Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Sherman on the Role of Regorafenib in Liver Cancer

January 14th 2017

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Dr. Pietrantonio on Survival Rates in Colorectal Cancer

January 14th 2017

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer

January 14th 2017

Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

January 13th 2017

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Dr. Venook on Advice for Oncologists Treating Patients With CRC

January 9th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, provides advice to community oncologists who are treating patients with colorectal cancer.

PEGPH20 Combo Improves PFS in Pancreatic Cancer

January 6th 2017

The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.

Dr. Marshall on Y-90 Mechanism of Action in Liver-Dominant CRC

January 5th 2017

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the mechanism of action of Yttrium-90 in the treatment of patients with liver-dominant, metastatic colorectal cancer.

FDA Grants Regorafenib Priority Review in Liver Cancer

January 4th 2017

The FDA has granted a priority review to a supplemental new drug application for the use of regorafenib as a second-line treatment for patients with unresectable hepatocellular carcinoma.

Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer

December 29th 2016

An immunotherapy combination that adds the interleukin-10 agonist AM0010 to FOLFOX chemotherapy will be evaluated in a phase III trial for patients with metastatic pancreatic cancer that could introduce a new modality to the treatment paradigm for the malignancy.

Dr. Braghioli on Molecular Characterization of CRC Tumors

December 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses a study exploring the various molecular characteristics of colorectal cancer (CRC) tumors.

Dr. Bekaii-Saab on the Role of Immunotherapy in CRC

December 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.

Dr. Venook on Important Factors for Treating Patients With CRC

December 20th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses important factors for oncologists to consider when treating patients with colorectal cancer.

Dr. Fedyanin on Future Treatment Landscape of CRC

December 20th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

Mutational Complexity Reflects Treatment Challenges for Hepatocellular Carcinoma

December 19th 2016

The growing incidence of primary liver cancer in the United States poses a great therapeutic challenge.

Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC

December 17th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the Expansion of Treatment Options in Colorectal Cancer

December 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

Targeted Therapy Makes Inroads in Gastroesophageal Cancer

December 15th 2016

Gastroesophageal cancer (GEC) is a complex disease, encompassing cancers with different histological and molecular subtypes. Growing insight into the molecular biology of GEC is poised to change the treatment landscape for this disease, although many questions remain unanswered.

Dr. Venook on Immunotherapy Potential in Colorectal Cancer

December 15th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.

Lancet Data Highlight OS Benefit for Regorafenib in HCC

December 9th 2016

Regorafenib (Stivarga) has demonstrated the first survival benefit for a systemic therapy in the second-line setting for patients with advanced hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar), according to results from the phase III RESORCE trial published in The Lancet.1

NEXT PAGE
PREVIOUS PAGE